A review on development of MUC1-based cancer vaccine

Gao, Tong; Cen, Qianhong; Han, Lei

doi:10.1016/j.biopha.2020.110888

Cited by 100 publications

(87 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Despite these advances, the detailed mechanisms by which MUC1 exerts its effects remain to be explored. Even though MUC1 vaccines and antibodies are being developed, with some having shown significant therapeutic effects and currently undergoing phase I/II clinical trials, certain side-effects and clinical safety issues need to be further explored and confirmed [ 3 , 109 , 110 ]. In conclusion, MUC1 is inextricably linked to various epithelial cancers, mandating further explorations of this phenomenon.…”

Section: Discussionmentioning

confidence: 99%

“…These two subunits are linked through stable hydrogen bonds [ 1 , 28 ]. However, in cancer-related MUC1, its structure was found to have changed—overexpressed due to loss polarity in epithelial cells, and the carbohydrate side chain becomes uncomplete and forms new carbohydrate side chains (Thomsen-Friedenreich (TF or T), Tn, and sialyl-Tn (STn)) and exposure of the core peptide ( Figure 1 B) [ 3 , 29 , 30 ].…”

Section: The Structure Of Muc1mentioning

confidence: 99%

“…It is the most readily recognized transmembrane protein of the mucin family and has a highly glycosylated extracellular domain. Under normal conditions, MUC1 covers the surface of all epithelial cells [ 1 , 2 , 3 ], forming a tight mesh. It forms a protective barrier through the mucosal surface and protects the cells from extreme environmental conditions [ 4 , 5 , 6 , 7 , 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

MUC1: Structure, Function, and Clinic Application in Epithelial Cancers

Chen

Zhu

Zhang

et al. 2021

IJMS

122

View full text Add to dashboard Cite

The transmembrane glycoprotein mucin 1 (MUC1) is a mucin family member that has different functions in normal and cancer cells. Owing to its structural and biochemical properties, MUC1 can act as a lubricant, moisturizer, and physical barrier in normal cells. However, in cancer cells, MUC1 often undergoes aberrant glycosylation and overexpression. It is involved in cancer invasion, metastasis, angiogenesis, and apoptosis by virtue of its participation in intracellular signaling processes and the regulation of related biomolecules. This review introduces the biological structure and different roles of MUC1 in normal and cancer cells and the regulatory mechanisms governing these roles. It also evaluates current research progress and the clinical applications of MUC1 in cancer therapy based on its characteristics.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: The Structure Of Muc1mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

MUC1: Structure, Function, and Clinic Application in Epithelial Cancers

Chen

Zhu

Zhang

et al. 2021

IJMS

122

View full text Add to dashboard Cite

show abstract

“…In addition to viral antigens, TAAs and TSAs are promising targets in designing therapeutic vaccines in HPV-negative HNCs, including mucin 1 (MUC1), carcinoembryonic antigen (CEA), and human telomerase reverse transcriptase (hTERT). MUC1 is a TM glycoprotein on the surface of nearly all epithelial cells that its aberrant expression is associated with malignant phenotype; thus, it is an ideal target for developing cancer vaccines [ 154 ]. A MUC1 vaccine combined with Tadalafil is under phase I clinical trial to treat HNCs (NCT02544880).…”

Section: Vaccinesmentioning

confidence: 99%

A review on the advances and challenges of immunotherapy for head and neck cancer

et al. 2021

View full text Add to dashboard Cite

Head and neck cancer (HNC), which includes lip and oral cavity, larynx, nasopharynx, oropharynx, and hypopharynx malignancies, is one of the most common cancers worldwide. Due to the interaction of tumor cells with immune cells in the tumor microenvironment, immunotherapy of HNCs, along with traditional treatments such as chemotherapy, radiotherapy, and surgery, has attracted much attention. Four main immunotherapy strategies in HNCs have been developed, including oncolytic viruses, monoclonal antibodies, chimeric antigen receptor T cells (CAR-T cells), and therapeutic vaccines. Oncorine (H101), an approved oncolytic adenovirus in China, is the pioneer of immunotherapy for the treatment of HNCs. Pembrolizumab and nivolumab are mAbs against PD-L1 that have been approved for recurrent and metastatic HNC patients. To date, several clinical trials using immunotherapy agents and their combination are under investigation. In this review, we summarize current the interaction of tumor cells with immune cells in the tumor microenvironment of HNCs, the main strategies that have been applied for immunotherapy of HNCs, obstacles that hinder the success of immunotherapies in patients with HNCs, as well as solutions for overcoming the challenges to enhance the response of HNCs to immunotherapies.

show abstract

“…Functionalization using lectins, glycoconjugates, and microbial ligands such as lipopolysaccharide and flagellin has been one of the ways to overcome the challenge of traversing the mucus barrier. Therefore, mimicking microorganisms approaches have shown favorable outcomes such as the induction of enhanced immune responses in several studies [20][21][22].…”

Section: Route Ofmentioning

confidence: 99%

Buccal and Sublingual Vaccines: A Review on Oral Mucosal Immunization and Delivery Systems

2021

View full text Add to dashboard Cite

Currently, most vaccines available on the market are for parental use; however, this may not be the best option on several occasions. Mucosal routes of administration such as intranasal, sublingual, and buccal generate great interest due to the benefits they offer. These range from increasing patient compliance to inducing a more effective immune response than that achieved through conventional routes. Due to the activation of the common mucosal immune system, it is possible to generate an effective systemic and local immune response, which is not achieved through parenteral administration. Protection against pathogens that use mucosal entry routes is provided by an effective induction of mucosal immunity. Mucosal delivery systems are being developed, such as films and microneedles, which have proven to be effective, safe, and easy to administer. These systems have multiple advantages over commonly used injections, which are simple to manufacture, stable at room temperature, painless for the patient since they do not require puncture. Therefore, these delivery systems do not require to be administered by medical personnel; in fact, they could be self-administered.

show abstract

A review on development of MUC1-based cancer vaccine

Cited by 100 publications

References 92 publications

MUC1: Structure, Function, and Clinic Application in Epithelial Cancers

MUC1: Structure, Function, and Clinic Application in Epithelial Cancers

A review on the advances and challenges of immunotherapy for head and neck cancer

Buccal and Sublingual Vaccines: A Review on Oral Mucosal Immunization and Delivery Systems

Contact Info

Product

Resources

About